Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00517101
Status:
UNKNOWN
Last Update Posted:
2007-08-16
First Post:
2007-08-15
Brief Title:
Presence of IBD Specific Antibodies ASCA ALCA ACCA AMCA in the Sera of Patients With Spondyloarthropathy
Sponsor:
Tel-Aviv Sourasky Medical Center
Organization:
Tel-Aviv Sourasky Medical Center
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2007-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A relationship between IBD and spondyloarthropathy is well recognized ASCA anti saccharomyces cerevisiae antibodiesare considered to be a serological marker for Crohns disease and have been studied in patients with spondyloarthropathy with conflicting results More recently new serological markers for IBD have been described These markers are antibodies to certain defined glycans and their use may permit an improved diagnosis of IBD
The aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy
The aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None